Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

2021 European Heart Journal 1,004 citations

Abstract

Abstract Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.

Keywords

MedicineCardiac amyloidosisAmyloidosisDiseasePosition statementCardiologyIntensive care medicineInternal medicine

Affiliated Institutions

Related Publications

Publication Info

Year
2021
Type
article
Volume
42
Issue
16
Pages
1554-1568
Citations
1004
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1004
OpenAlex

Cite This

Pablo García‐Pavía, Claudio Rapezzi, Yehuda Adler et al. (2021). Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal , 42 (16) , 1554-1568. https://doi.org/10.1093/eurheartj/ehab072

Identifiers

DOI
10.1093/eurheartj/ehab072